Skip to content

Achieve Life Sciences ACHV Receivable from credits from ARPA

Receivable from credits from ARPA at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$6.2M+265%
ATN International logo
ATN InternationalATNI
$37.46M
Clarivate logo
ClarivateCLVT
$1.3M-31.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$15.69M+563%
Western Digital logo
Western DigitalWDC
$1.89B+28.9%
Liberty Media Corporation logo
Liberty Media CorporationFWONK
$262M+81.9%

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0
Free cash flow-$12.4M

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:GrantsReceivableCurrent.

The official record: Achieve Life Sciences’s 10-K, filed March 11, 2025, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's receivable from credits from arpa.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's receivable from credits from ARPA?
Achieve Life Sciences (ACHV) reported receivable from credits from ARPA of $111K in Q4 2023.
How has Achieve Life Sciences's receivable from credits from ARPA changed year-over-year?
Achieve Life Sciences's receivable from credits from ARPA increased by 5.7% year-over-year, from $105K to $111K.
What is the long-term trend for Achieve Life Sciences's receivable from credits from ARPA?
Over 2 years (2021 to 2023), Achieve Life Sciences's receivable from credits from ARPA has grown at a -14.8% compound annual growth rate (CAGR), from $153K to $111K.